5 assets in Adult Acute Monocytic Leukemia

Therapeutic assets addressing Adult Acute Monocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Adult Acute Monocytic Leukemia	Northwestern University	P3	BBB (76)
Daunomycin Adult Acute Monocytic Leukemia	National Cancer Institute (NCI)	P3	BBB (74)
Azacitidine Adult Acute Monocytic Leukemia	University of Chicago	P2	BB (69)
Decitabine Adult Acute Monocytic Leukemia	Roswell Park Cancer Institute	P3	BB (66)
Gemtuzumab Ozogamicin Adult Acute Monocytic Leukemia	National Cancer Institute (NCI)	P2	BB (64)